Abstract: Hepatitis B virus infection (HBV) is the major risk factor for hepatocarcinogenesis in China,and the HBV-DNA level also influences the postoperative complications ratio.A lot of research has confirmed that HBV-DNA replication could lead to the tumor recurrence after liver resection.Some clinical research aimed to find whether anti-HBV therapy can prevent the relapse of hepatocellular carcinoma (HCC).At present,majority study confirm that anti-HBV therapy can reduce tumor recurrence ratio of HCC,but some researches find it is useless for the relapse preventing,however,it can prolong the patients survival period.Above all,as for HBV related HCC,anti-HBV therapy plays an important role in the whole HCC therapy process including perioperative treatment and HCC relapse prevention.So,we must pay attention to anti-HBV therapy in HCC treatment.

Key words: Hepatocellular carcinoma, Hepatitis B virus, Disease treatment